Mary Bird Perkins Cancer Center is adding additional strength to its medical staff leadership team. Daniel LaVie, MD, has been appointed as medical director of hematology and medical oncology, and Constance Blunt, MD, will serve as medical director of cancer prevention and outreach.
In his role as medical director of hematology and medical oncology, LaVie, who has been with Mary Bird Perkins since 2018, will provide strategic oversight and clinical guidance for the Center's medical oncology programs. He will define and implement strategies to optimize cancer care, enhance patient outcomes, and lead continuous improvements in clinical practice. He will also collaborate with multiple leaders across the organization, including the Cancer Center’s administrator, and its quality program to ensure excellence in patient care and compliance with regulatory standards.
As medical director of cancer prevention and outreach, Blunt, who has worked at Mary Bird Perkins since 2022, will work closely with vice president for cancer support and outreach Renea Duffin, and the program’s regional directors to guide and enhance the Prevention on the Go program. Blunt will provide medical leadership, establish strategic priorities, and help to drive quality improvement in cancer prevention and early detection services.
Blunt will focus on strategic planning, staff development, and program evaluation while actively participating in community events and media outreach to promote cancer prevention, education, and awareness.
“Drs. LaVie and Blunt’s combined expertise in hematology, medical oncology, and cancer prevention is a tremendous asset as we continue to advance our mission of providing exceptional care and innovative solutions. Their strategic vision and dedication to oncology will be instrumental in further enhancing our programs and driving impactful outcomes for our patients and community,” saidJodi Conachen, chief operating officer, Mary Bird Perkins Cancer Center.